Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations

Lisa R. Forbes(Baylor College of Medicine), Jennifer W. Leiding(Johns Hopkins University), Helen C. Su(National Institutes of Health), Katja G. Weinacht(Stanford Medicine), Paul Szabolcs(University of Pittsburgh), Charlotte Cunningham‐Rundles, Edith Schussler(Icahn School of Medicine at Mount Sinai), R. Paul Guillerman(Baylor College of Medicine), Tiphanie P. Vogel(Baylor College of Medicine), Eric J. Allenspach(Center for Infectious Disease Research), Peter Olbrich(University of Regensburg), Johana B Castro-Wagner(University of South Florida St. Petersburg), Yeşim Yılmaz Demirdağ(Morgan Stanley Children's Hospital), Joshua D. Milner(National Institutes of Health), Megan A. Cooper(Washington University in St. Louis), Alexandra F. Freeman(National Institutes of Health), Ashley Plant(Children's Hospital of Orange County), Niraj Patel(Levine Children's Hospital), Troy R. Torgerson(Allen Institute for Immunology), Mary Slatter(Great North Children's Hospital), Olive S. Eckstein(Children's Cancer Center), Christa S. Zerbe(National Institutes of Health), Mario Abinun(North Tyneside General Hospital), Desa Lilić(Newcastle University), Steven M. Holland(National Institutes of Health), Andrew R. Gennery(Hôpital Necker-Enfants Malades)
Journal of Allergy and Clinical Immunology
August 6, 2018
Cited by 261


Related Papers